StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Constant Currency Growth in Rest of World (% cc) by Quarter

Constant Currency Growth in Rest of World (% cc) (%)

QuarterlyAnnual

Novartis Constant Currency Growth in Rest of World (% cc): 65.0% in Q3 2026, up 2.0 pts from a year earlier.

Latest, Q3 2026
65.0%
Period ended Sep 30, 2026
Change on a year earlier
+2.0 pts
63.0% in Q3 2025
History
11 quarters
Since Q1 2024
Sources
11
Documents cited below

Where the Q3 2026 figure comes from

“|| Leqvio | Cardiovascular, renal and metabolic | Atherosclerotic cardiovascular disease (ASCVD) | 234 | 60 | 272 | 68 | 65 | 506 | 64 | 63”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedConstant Currency Growth in Rest of World (% cc) (%)Year on yearSource
Q3 2026Sep 30, 202665.0%+2.0 ptsNovartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 202663.0%-11.0 ptsNovartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026106.0%+32.0 ptsNovartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 202552.0%-47.0 ptsNovartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 202563.0%-114.0 ptsNovartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 202574.0%-91.0 ptsNovartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 202574.0%-114.0 ptsNovartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 202499.0%–Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 2024177.0%–Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 2024165.0%–Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2024Mar 31, 2024188.0%–Novartis Form 6-K (0001370368-24-000017) ↗

Cite this data

StockData. (2026). Novartis Constant Currency Growth in Rest of World (% cc) (%), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-leqvio-row-yoy-cc-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.